We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging ChromaDex (CDXC) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is ChromaDex one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
ChromaDex is a member of our Medical group, which includes 1025 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. ChromaDex is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for CDXC's full-year earnings has moved 142.9% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that CDXC has returned about 140.6% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 7.5% on a year-to-date basis. This means that ChromaDex is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Bioventus (BVS - Free Report) . The stock has returned 138.1% year-to-date.
Over the past three months, Bioventus' consensus EPS estimate for the current year has increased 48.2%. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, ChromaDex belongs to the Medical - Biomedical and Genetics industry, a group that includes 504 individual companies and currently sits at #88 in the Zacks Industry Rank. This group has gained an average of 0.3% so far this year, so CDXC is performing better in this area.
On the other hand, Bioventus belongs to the Medical - Drugs industry. This 171-stock industry is currently ranked #71. The industry has moved -1.1% year to date.
Investors with an interest in Medical stocks should continue to track ChromaDex and Bioventus. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging ChromaDex (CDXC) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is ChromaDex one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
ChromaDex is a member of our Medical group, which includes 1025 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. ChromaDex is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for CDXC's full-year earnings has moved 142.9% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that CDXC has returned about 140.6% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 7.5% on a year-to-date basis. This means that ChromaDex is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Bioventus (BVS - Free Report) . The stock has returned 138.1% year-to-date.
Over the past three months, Bioventus' consensus EPS estimate for the current year has increased 48.2%. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, ChromaDex belongs to the Medical - Biomedical and Genetics industry, a group that includes 504 individual companies and currently sits at #88 in the Zacks Industry Rank. This group has gained an average of 0.3% so far this year, so CDXC is performing better in this area.
On the other hand, Bioventus belongs to the Medical - Drugs industry. This 171-stock industry is currently ranked #71. The industry has moved -1.1% year to date.
Investors with an interest in Medical stocks should continue to track ChromaDex and Bioventus. These stocks will be looking to continue their solid performance.